Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
| dc.contributor.author | Roboz, Gail J. | |
| dc.contributor.author | Sanz, Guillermo | |
| dc.contributor.author | Griffiths, Elizabeth A. | |
| dc.contributor.author | Yee, Karen | |
| dc.contributor.author | Kantarjian, Hagop | |
| dc.contributor.author | Récher, Christian | |
| dc.contributor.author | Byrne, Michael T. | |
| dc.contributor.author | Patkowska, Elżbieta | |
| dc.contributor.author | Kim, Hee-Je | |
| dc.contributor.author | Thomas, Xavier | |
| dc.contributor.author | Moors, Ine | |
| dc.contributor.author | Stock, Wendy | |
| dc.contributor.author | Illés, Árpád | |
| dc.contributor.author | Fenaux, Pierre | |
| dc.contributor.author | Miyazaki, Yasushi | |
| dc.contributor.author | Yamauchi, Takahiro | |
| dc.contributor.author | O'Connell, Casey L. | |
| dc.contributor.author | Hao, Yong | |
| dc.contributor.author | Keer, Harold N. | |
| dc.contributor.author | Azab, Mohammad | |
| dc.contributor.author | Döhner, Hartmut | |
| dc.date.accessioned | 2024-07-24T10:00:32Z | |
| dc.date.available | 2024-07-24T10:00:32Z | |
| dc.date.issued | 2024 | |
| dc.date.oa | 2025-01-31 | |
| dc.date.pasync | 2024-08-06T23:07:07Z | |
| dc.date.updated | 2024-07-24T10:00:32Z | |
| dc.description.corrector | LB | |
| dc.identifier.citation | Blood Advances. -8 : 8 (2024), p. 2020-2029. -Blood Adv. - 2473-9529. - 2473-9537 | |
| dc.identifier.doi | http://dx.doi.org/10.1182/bloodadvances.2023012062 | |
| dc.identifier.issn | 2473-9537 | |
| dc.identifier.issn | 2473-9529 | |
| dc.identifier.opac | https://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM122910 | |
| dc.identifier.scopus | 85191585888 | |
| dc.identifier.uri | https://hdl.handle.net/2437/377057 | |
| dc.identifier.url | https://ashpublications.org/bloodadvances/article/8/8/2020/514602/Guadecitabine-vs-TC-in-relapsed-refractory-AML | |
| dc.identifier.wos | 001235287300001 | |
| dc.language | eng | |
| dc.rights.access | open access article | |
| dc.rights.owner | The American Society of Hematology | |
| dc.subject.mab | Orvostudományok | |
| dc.subject.mab | Klinikai orvostudományok | |
| dc.title | Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial | |
| dc.type | folyóiratcikk | |
| dc.type | idegen nyelvű folyóiratközlemény külföldi lapban |
Fájlok
Eredeti köteg (ORIGINAL bundle)
1 - 1 (Összesen 1)
Nincs kép
- Név:
- FILE_UP_0_blooda_adv-2023-012062-main.pdf
- Méret:
- 1.24 MB
- Formátum:
- Adobe Portable Document Format
- Leírás:
- Kiadói változat